Chaim Roifman

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Business Development Bank of Canada provides commercial banking services. It offers business loans and consulting services to help Canadian businesses grow, both at home and abroad. The firm also offers a full spectrum of specialized financing, including venture capital, equity as well as growth and business transition capital through its subsidiaries. The company was founded in 1995 and is headquartered in Montreal, Canada.

GrowthWorks Capital Ltd. (GrowthWorks) is a venture capital firm founded in 1992 by David Levi. The firm is headquartered in Vancouver, Columbia with additionaal offices in Saskatchewan, Manitoba, New Brunswick, Newfoundland, Nova Scotia, and Ontario.

BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada.

GeneChem Management Inc (GeneChem) is an independent venture capital firm founded in 1997. The firm is headquartered in Montréal.

Genome Canada provides genomic research services. It connects ideas and people across public and private sectors to find new uses for genomics, invests in large-scale science and technology to fuel innovation,and translates discoveries into applications, new technologies, societal impacts and solutions across key sectors of national importance, including health, agriculture, forestry, fisheries and aquaculture, energy, mining, and the environment. The company was founded in 2000 and is headquartered in Ottawa, Canada.

Founded in 1996, Novartis Pharma NV is a Belgian pharmaceutical company that develops medicines. The company is based in Brussels, Belgium and is a subsidiary of Novartis AG.

AgeChem Financial, Inc. engages in the provision of investment services, It seeks to invest in companies developing therapeutics targeting age-related diseases. The company was founded in 2006 and is headquartered in Montreal, Canada.

Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada.

Sanofi-aventis Canada Inc. is the Canadian affiliate of the sanofi-aventis Group, one of the world's leading pharmaceutical companies. They are headquartered in Laval, Quebec, and employ 900 people across the country. Their Laval site is also home to a world-class manufacturing facility that produces medications for use by patients in Canada, the United States and other countries. As a leading healthcare partner they provide, and are developing, innovative medicines for treatments in several therapeutic areas: cardiovascular disease, thrombosis, oncology, metabolic disorders, the central nervous system, and internal medicine. They also play a role by investing in activities that improve health and quality of life in their communities. The sanofi-aventis Group is also represented in Canada by Sanofi Pasteur Limited. Located in Toronto, the company is Canada's largest producer of vaccines and employs 1,200 people.

AmorChem Financial, Inc. provides financial investment services. The company is headquartered in Westmount, Canada.

Insitut de Recherche en Immunologie et en Cancérologie develops and discovers treatment and therapies for cancers. It also engages in anticancer drug discovery chain. The company was founded in 2003 and is headquartered in Montréal, Canada.

Cyclenium Pharma, Inc. is a privately held pharmaceutical research and development company based in Montréal, Canada. The Canadian company is focused on creating value through the progression of internal programs in oncology, infectious diseases, and inflammation/pain. Cyclenium is also providing its extensive experience and exploring its CMRT-based Quest™ screening library in risk-sharing partnerships with leading academic and research-driven non-profit organizations, as well as collaborations with innovative pharmaceutical and biotechnology companies worldwide seeking to modulate unique and difficult disease targets in diverse therapeutic areas. The company was founded by Mark L. Peterson, and the CEO is Helmut Thomas.

Corbin Therapeutics, Inc. operates as a biotechnology platform.

Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021.